Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average - Here's Why

Key Points

• Cellectis shares crossed above their 50-day moving average, reaching $3.11 before closing at $3.04; the stock’s 50-day average was $2.93.
• Analyst views are mixed, but the overall consensus is “Moderate Buy” with a $7.00 price target. Barclays initiated coverage with an “overweight” rating and a $9.00 target, while Weiss Ratings maintained a sell rating.
• Cellectis beat quarterly EPS expectations, reporting a loss of $0.22 per share versus the expected $0.26 loss, but revenue of $6.90 million fell short of the $11.05 million consensus estimate. Institutional investors own 63.9% of the company.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.93 and traded as high as $3.11. Cellectis shares last traded at $3.04, with a volume of 24,180 shares trading hands.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Barclays started coverage on shares of Cellectis in a research note on Thursday, May 28th. They issued an "overweight" rating and a $9.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cellectis in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Cellectis Stock Down 2.3%

The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The company has a fifty day simple moving average of $2.93 and a 200-day simple moving average of $3.41. The firm has a market cap of $305.03 million, a P/E ratio of -4.68 and a beta of 2.91.

Cellectis (NASDAQ:CLLS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. Cellectis had a negative return on equity of 94.19% and a negative net margin of 102.34%.The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million.

Hedge Funds Weigh In On Cellectis

Several large investors have recently added to or reduced their stakes in the company. Lido Advisors LLC purchased a new stake in shares of Cellectis in the first quarter worth $32,000. Marshall Wace LLP boosted its holdings in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock worth $864,000 after buying an additional 168,038 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Cellectis in the 4th quarter worth $15,385,000. Global Retirement Partners LLC purchased a new stake in Cellectis in the 4th quarter worth $34,000. Finally, Millennium Management LLC increased its stake in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock worth $165,000 after buying an additional 22,080 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source